<DOC>
	<DOCNO>NCT00093990</DOCNO>
	<brief_summary>The purpose study determine effectiveness tipifarnib patient age 70 acute myeloid leukemia . Tipifarnib belong class drug call Farnesyl Transferase Inhibitors ( FTI ) . It block protein make leukemia cell grow .</brief_summary>
	<brief_title>Tipifarnib Versus Best Supportive Care Treatment Newly Diagnosed Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>This study test safety effectiveness experimental drug , tipifarnib old patient acute myeloid leukemia ( AML ) . The purpose study test tipifarnib make patient leukemia live longer . In study , half patient receive tipifarnib half patient receive standard treatment . The standard treatment help control symptom AML may include hydroxyurea low level circulate leukemia cell . Tipifarnib standard treatment give patient 's leukemia get well , experience unacceptable side effect , patient study doctor decide stop study medication . Patients assign tipifarnib give tipifarnib tablet . Patients take 6 tablet food morning 6 tablet food evening , 21 day row . Patients take tipifarnib next 7 day . This 28 day period call cycle . The rest period may extend beyond 7 day depend well patient tolerate treatment . Patients return study clinic every week visit study doctor least every two week . A blood draw routine test do every week . Depending disease , bone marrow aspiration may do end every cycle . When patient finish treatment study medication , leave study early , ask see doctor one last visit . Routine laboratory test do . After visit study doctor continue check patient see started new treatment leukemia . This check make every 30 day may make phone patient health care provider . Tipifarnib ; six 100 mg film coat , compressed tablet give orally twice day 21 consecutive day 28-day cycle schedule .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Newly diagnose relapse AML Patient medically fit combination induction chemotherapy Pathologic confirmation AML ( = &gt; 20 % bone marrow leukemic blast ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Previous cytotoxic biologic treatment AML Acute promyelocytic leukemia ( APL ) Central nervous system leukemia Uncontrolled systemic infection Uncompensated disseminate intravascular coagulation Symptomatic neuropathy grade 2 bad Known allergy imidazole drug .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Myeloid leukemia acute disease</keyword>
	<keyword>Tipifarnib</keyword>
	<keyword>Bone marrow aspirate</keyword>
</DOC>